Lineage Cell Therapeutics Statistics
Share Statistics
Lineage Cell Therapeutics has 228.36M
shares outstanding. The number of shares has increased by 20.94%
in one year.
| Shares Outstanding | 228.36M |
| Shares Change (YoY) | 20.94% |
| Shares Change (QoQ) | 3.6% |
| Owned by Institutions (%) | 56.71% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,978 |
| FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 29.96M, so 13.12% of the outstanding
shares have been sold short.
| Short Interest | 29.96M |
| Short % of Shares Out | 13.12% |
| Short % of Float | 23.42% |
| Short Ratio (days to cover) | 40.09 |
Valuation Ratios
The PE ratio is -5.41 and the forward
PE ratio is -13.25.
Lineage Cell Therapeutics's PEG ratio is
0.22.
| PE Ratio | -5.41 |
| Forward PE | -13.25 |
| PS Ratio | 10.59 |
| Forward PS | 3.6 |
| PB Ratio | 1.28 |
| P/FCF Ratio | -4.25 |
| PEG Ratio | 0.22 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Lineage Cell Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.65,
with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.65 |
| Quick Ratio | 3.65 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.11 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $135,700 |
| Profits Per Employee | $-265,842.86 |
| Employee Count | 70 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 27K |
| Effective Tax Rate | -0.15% |
Stock Price Statistics
The stock price has increased by -31.11% in the
last 52 weeks. The beta is 1.52, so Lineage Cell Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.52 |
| 52-Week Price Change | -31.11% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 67.53 |
| Average Volume (20 Days) | 1,355,146 |
Income Statement
In the last 12 months, Lineage Cell Therapeutics had revenue of 9.5M
and earned -18.61M
in profits. Earnings per share was -0.09.
| Revenue | 9.5M |
| Gross Profit | 9.16M |
| Operating Income | -21.48M |
| Net Income | -18.61M |
| EBITDA | -20.87M |
| EBIT | -21.48M |
| Earnings Per Share (EPS) | -0.09 |
Full Income StatementBalance Sheet
The company has 45.79M in cash and 2.51M in
debt, giving a net cash position of 43.27M.
| Cash & Cash Equivalents | 45.79M |
| Total Debt | 2.51M |
| Net Cash | 43.27M |
| Retained Earnings | -403.46M |
| Total Assets | 111.75M |
| Working Capital | 36.9M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -23.09M
and capital expenditures -565K, giving a free cash flow of -23.66M.
| Operating Cash Flow | -23.09M |
| Capital Expenditures | -565K |
| Free Cash Flow | -23.66M |
| FCF Per Share | -0.12 |
Full Cash Flow StatementMargins
Gross margin is 96.48%, with operating and profit margins of -226.11% and -195.9%.
| Gross Margin | 96.48% |
| Operating Margin | -226.11% |
| Pretax Margin | -195.62% |
| Profit Margin | -195.9% |
| EBITDA Margin | -219.7% |
| EBIT Margin | -226.11% |
| FCF Margin | -249.05% |
